COMMUNIQUÉS West-GlobeNewswire

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
22/09/2026
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy [...]
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
22/09/2026
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at https://lythampartners.com/fall2026/ [...]
Novo and UNICEF expand partnership to support a healthier start for more than 80 million children
22/09/2026
The four-year expansion will focus on childhood overweight and obesity prevention for over 80 million children across seven priority countries: Mexico, Colombia, Indonesia, the Philippines, India, Egypt and Kenya Novo [...]
Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System
22/09/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and has completed the first surgical cases with [...]
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
22/09/2026
New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industry JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or [...]
Clene to Present at Upcoming Investor Conferences
22/09/2026
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5 th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners [...]
Envisagenics and Boehringer Ingelheim Enter Multi-Target Collaboration to Develop First-in-Class Precision Therapies Based on RNA Splicing-Derived Targets for Hard-to-Treat Cancers
22/09/2026
Envisagenics’ AI-powered SpliceCore ® platform opens up alternative RNA splicing – one of the last largely untapped sources of tumor-specific targets – for precision oncology Boehringer Ingelheim may apply selected [...]
Adventist Health Bakersfield Introduces Kern County’s First Next Generation Robotic-Assisted Bronchoscopy
22/09/2026
Advanced technology helps physicians detect lung cancer earlier and improve treatment BAKERSFIELD, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Kern County and surrounding areas now have access to a next-generation, [...]
Medera Expands Singapore Presence Through Partnership with National Heart Centre Singapore
22/09/2026
Medera establishes Singapore laboratory and office to support human mini-heart cardiac disease modeling, drug discovery, and regional cardiovascular clinical innovation BOSTON and SINGAPORE, Sept. 22, 2026 (GLOBE [...]
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
22/09/2026
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision [...]
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
22/09/2026
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential [...]
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
22/09/2026
HepaRegeniX to seamlessly advance darizmetinib’s clinical development to Phase 2a following completion of the Phase 1b in 2026 Tuebingen, Germany, September 22, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage [...]
Transactions in connection with share buy-back program
22/09/2026
Company announcement no. 36 - 26 22 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Bavarian Nordic – Notification of Holding of Treasury Shares
22/09/2026
COPENHAGEN, Denmark, September 22, 2026 - Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that as of September 21, 2026, Bavarian Nordic’s holding of treasury shares amounted to 3,965, [...]
AstronauTx awarded research funding from The Michael J. Fox Foundation and Parkinson’s UK to explore sleep-based approaches for Parkinson's disease
22/09/2026
MJFF grant will support development of a potential disease-modifying treatment for prodromal Parkinson's disease by targeting restorative sleep mechanisms Parkinson's UK-funded research with University College London ( [...]
Dialybrid secures €15 million series A round and announces successful first-in-human implant of novel Silkothane® Arteriovenous Graft for vascular access in hemodialysis
22/09/2026
Silkothane® Arteriovenous Graft is a novel hybrid arteriovenous graft engineered to integrate into patients’ vessels and provide a safe, easy-to-cannulate, durable, vascular access for hemodialysis in patients with end- [...]
Opterion Health Announces Positive Phase 1 Results for OPT101, Supporting Advancement to Phase 2a
22/09/2026
SPARC study achieved all its objectives, establishing a strong clinical foundation for a differentiated, non-glucose-based treatment for peritoneal dialysis Positive Phase 1 results strengthen confidence in OPT101 , [...]
HighLife Raises $90+ Million to start its US Pivotal Study and accelerate Commercial Expansion in Europe
22/09/2026
Paris, France, September 22 – HighLife SAS, a MedTech company focused on transcatheter solutions for structural heart disease, today announced the successful completion of a $90+ Million (€80 Million) financing round . [...]
HighLife lève plus de 90 millions de dollars pour lancer son étude pivot aux États-Unis et accélérer son développement commercial en Europe
22/09/2026
Paris, France - le 22 septembre 2026 – HighLife SAS, Medtech spécialisée dans les solutions transcathéter destinées au traitement des maladies cardiaques structurelles, annonce aujourd’hui avoir réalisé avec succès une [...]

Pages